Candesartan and losartan do not affect the
pharmacokinetics of
tacrolimus. Concur- rent use with angiotensin II
receptor antagonists may increase the risk of developing hyperkalaemia and/or nephrotoxicity in those taking
tacrolimus.
Both
renal function and potassium levels should be monitored if angiotensin II
receptor antagonists are given with
tacrolimus.